Skip to main content
Laurus Labs Limited logo

Laurus Labs Limited — Investor Relations & Filings

Ticker · LAURUSLABS ISIN · INE947Q01028 LEI · 335800S8HO8QRYP3VQ26 BSE.NS Manufacturing
Open in API
Filings indexed 707 across all filing types
Latest filing 2020-12-08 Investor Presentation
Country IN India
Listing BSE.NS LAURUSLABS

About Laurus Labs Limited

https://www.lauruslabs.com/

Laurus Labs Limited is a research-driven organization focused on the development and manufacturing of active pharmaceutical ingredients (APIs), finished dosage forms (FDF), and specialized synthesis services. The company operates across several key therapeutic areas, including anti-retroviral (ARV), oncology, cardiovascular, and anti-diabetic treatments. Through its contract development and manufacturing organization (CDMO) division, it provides integrated drug development solutions to global partners. The company also maintains a biotechnology segment dedicated to recombinant products. Leveraging advanced research and development capabilities alongside large-scale manufacturing infrastructure, the firm emphasizes process chemistry innovation and cost-efficient production to serve diverse global healthcare markets.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 85% confidence The document is very short (624 characters) and contains information about a virtual group meeting with analysts and investors, specifically mentioning a date and the type of interaction (Group Meetings - Virtual NDR). There is no financial data, no detailed report, no regulatory filing, or announcement of voting results. The content aligns with an investor presentation or investor relations event summary. Given the nature of the content, it best fits the category of Investor Presentation (IP).
2020-12-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of a conference call discussing Laurus Labs Ltd's acquisition of Richcore Lifesciences Pvt. Ltd. It includes detailed discussions by company executives and analysts about the acquisition, financials, strategic rationale, and future plans. The presence of a moderator, Q&A session, and the format of the text clearly indicate this is a full transcript of a conference call. The content focuses on the acquisition and related financial and strategic details, typical of an investor call transcript. Therefore, the document fits the category of a Call Transcript (CT).
2020-12-02 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is extremely short (193 characters) and contains only a brief table with a date, an analyst/investor event name, and type of interaction. There is no financial data, no report content, no regulatory references, or detailed information. It appears to be a simple schedule or record of an investor interaction event, likely a virtual non-deal roadshow (NDR). This does not fit any detailed report or announcement category. Given the brevity and nature, it best fits the fallback category Regulatory Filings (RNS) as a general regulatory announcement or miscellaneous filing.
2020-12-02 English
Related Party Transactions
Management Reports Classification · 85% confidence The document contains detailed disclosures about related party transactions, including names and relationships of key management personnel, enterprises influenced by them, and financial transactions such as salaries, commissions, donations, and rent paid. The content is typical of notes to financial statements or disclosures related to governance and management remuneration. The document length is 2573 characters, which is relatively short and does not contain comprehensive financial statements or full report content. It does not appear to be a full Annual Report (10-K) or Interim Report (IR). It is also not a certification or announcement. The content fits best under Management Reports (MDA), which include management's detailed explanations and disclosures about financial results and business relationships, including related party transactions.
2020-11-26 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2020-11-25 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is an announcement of a conference call scheduled for November 26, 2020, regarding Laurus Labs Ltd.'s acquisition of a majority stake in Richcore Lifesciences. It includes details for investors and analysts to join the call, such as dial-in numbers and registration links. There is no substantive financial data, detailed report, or transcript included. The document is short (2436 characters) and serves as an invitation and informational notice about the upcoming call rather than the call transcript itself or a detailed report. Therefore, it fits best into the category of a Call Transcript announcement or invitation, but since it is only announcing the call and not providing the transcript, the closest fitting category is Call Transcript (CT) as it relates to the conference call content. Confidence is high given the clear context and content type.
2020-11-25 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.